What is claimed is:

A compound of the formula

5~/l/>

10

15

25

H N X R

5 /including a pharmaceutically acceptable salt thereof wherein

x is 0 or 1,


R is H, alkyl, alkenyl, aryl- $(CH_2)_p$ -, heteroaryl- $(CH_2)_p$ -, cycloheteroalkyl- $(CH_2)_p$ -, or

R can be joined together with the carbon to which it is attached to form a 3 to 7 membered ring which may optionally be fused to a benzene ring;

 $\rm R^1$ is H or -COR² where R² is alkyl, aryl- (CH₂)_p-, cycloheteroalkyl-(CH₂)_p-, heteroaryl-(CH₂)_p-, alkoxy or cycloalkyl-(CH₂)_p-; \

p is 0 or an integer from 1 to 8; and
A is a dipeptide derived from one or two nonproteinogenic amino acids or is a conformationally
restricted dipeptide mimic.

20 2. The compound as defined in Claim 1 wherein A is a dipeptide derivative of the structure



wherein R^{1a} , R^{1b} , R^{2a} and R^{2b} are independently selected from H, alkyl, aryl- $(CH_2)_p$ -, cycloalkyl, cycloheteroalkyl- $(CH_2)_p$ -, heteroaryl- $(CH_2)_p$ -, biphenylmethyl, or

 R^{1a} and R^{1b} or R^{2a} and R^{2b} may be joined together to the carbon to which it is attached to form a 3 to 7 membered ring, optionally fused to a

R³ R⁵


benzene ring; and $-R^{2b}$ refers to an optional 5 or 6 membered ring containing a single hetero atom and which may optionally include an R⁵ substituent which is H, alkyl, aryl-(CH₂)_p, cycloalkyl-(CH₂)_p, cycloheteroalkyl-(CH₂)_p or

5 cycloalkyl-(CH₂)_p, cycloheteroalkyl-(CH₂)_p or cycloheteroaryl-(CH₂)_p-;

 R^3 is H alkyl or aryl $-(CH_2)_p$ -;

 R^4 is OH, Oalkyl, Oaryl- $(CH_2)_p$ - or $NR_1(R_2)$ where R_1 and R_2 are independently H, alkyl, aryl, aryl $(CH_2)_p$ or heteroaryl $(CH_2)_p$;

with the proviso that in A(1) at least one of




is other than a natural α -amino acid.

3. The compound as defined in Claim 1 wherein A is a conformationally restricted dipeptide mimic.


4. The compound as defined in Claim 3 wherein the conformationally restricted dipeptide mimic has the structure

20

15



5. The compound as defined in Claim 3 wherein A has the formula



with respect to A(5), R^{11} and R^{12} are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl -(CH₂)_p-, aryl -(CH₂)_p-, and heteroaryl -(CH₂)_p-, or R^{11} and R^{12} taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, or R^{11} and R^{12} taken together with the carbon to which they are attached complete a keto substituent,

with respect to A(13), R^8 , R^9 and R^7 are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl -(CH₂)_m-, aryl-(CH₂)_m-, and heteroaryl-(CH₂)_m-;

 R^{10} and R^6 are independently selected from hydrogen, alkyl alkenyl, cycloalkyl $-(CH_2)_{p^-}$, aryl- $(CH_2)_{p}$, and heteroaryl- $(CH_2)_{p^-}$, or R^6 and R^{10} taken together with the carbons to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, R^6 and R^8 taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons, or R^9 and R^{10} taken together with the carbon to which they are attached complete a saturated cycloalkyl ring of 3 to 7 carbons:

R⁴ is OH, Oalkyl, O-(CH₂)_p-heteroaryl,

 $NR_1(R_2)$ where R_1 and R_2 are independently H, alkyl, aryl, aryl-(CH₂)_p or heteroaryl;

 R^{14} is hydrogen, alkyl, cycloalkyl, or phenyl; R^{15} is hydrogen, alkyl, alkoxy or phenyl; R^{16} is alkyl or anyl-(CH₂)_m-; and

30

25

R¹⁷ is hydrogen, alkyl, substituted alkyl, alkenyl, cycloalkyl-(CH2) $_{m}$ -, aryl-(CH2) $_{m}$ -, or heteroary1-(CH2)m-.

 R^{18} is H of alkyl or alkenyl, and R^{18} and R^{17} 5 may be taken together with the carbon and nitrogen to which they are attached to complete a saturated Ncontaining ring of \$\phi\$ or 6 ring members.

R¹⁹ is H or anyletkyl, and in A(4), R¹⁹ and X (which is CH2) together with the carbons to which they are attached may form an aromatic ring of carbons (as in A(15).

6. The compound as defined in Claim 1 wherein

15

10

A is where n is 0 where $Y = O, S, CH_2, S(O)_{0,1,2}$

where $X^1 = H$, Ph, NHSO₂R⁵ (where R⁵ H)

where $Y = O, S, CH_2, S(O)_{0,1,2}$

The compound as defined in Claim 6 wherein

A is

5

15

where $Y = O, S, CH_2, S(O)_{0,1,2}$ where Y = O, S, CH_2 , $S(O)_{0,1,2}$

- 8. The compound as defined in Claim 1 wherein R1 is H, R is alkyl or arylalkyl, R4 is OH.
 - The compound as defined in Claim 2 where in A(1)



is a non-proteinogenic arine acid portion.

- 10. The compound as defined in Claim 9 wherein R^{1a} and R^{1b} are independently alkyl or arylalkyl, or Rla and Rlb together with the carbon to which they are attached form a\3 to 7 membered ring; or one of Rla and Rlb is biphenylmethylene and the 20 other is biphenylmethylene or H.
 - 11. The compound as defined in Claim 9 where in A(1),



is a non-proteinogenic amino acid where R³ is H, alkyl or arylalkyl,

 R^{2a} and R^{2b} are independently selected from H, alkyl, aryl or arylalkyl, with at least one of R^{2a} and R^{2b} being other than H, or R^{2a} and R^{2b} together with the carbon to which they are attached form a 3 to 7 membered ring.

- 12. A pharmaeutical composition comprising a therapeutically effective amount of a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.
- 13. The pharmaceutical composition as defined in Claim 12 useful in the treatment of cardiovascular diseases such as hypertension and/or congestive heart failure.
- 14. A method of treating a cardivascular disease such as hypertension and/or congestive heart failure, which comprises administering to a mammalian species a therapeutically effective amount of a composition as defined in Claim 12.
 - 15. The compound as defined in Claim 1 which

HO CO2H

15

20

is

10

5

or a pharmaceutically acceptable salt thereof.